Strides Arcolab is currently trading at Rs. 758.60, up by 34.20 points or 4.72% from its previous closing of Rs. 724.40 on the BSE.
The scrip opened at Rs. 729.00 and has touched a high and low of Rs. 760.05 and Rs. 729.00 respectively. So far 62,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 794.00 on 18-Jul-2012 and a 52 week low of Rs. 276.25 on 22-Aug-2011.
Last one week high and low of the scrip stood at Rs. 760.80 and Rs. 720.00 respectively. The current market cap of the company is Rs. 4,445 crore.
The promoters holding in the company stood at 28.27% while Institutions and Non-Institutions held 54.03% and 17.70% respectively.
Strides Arcolab’s wholly owned subsidiary Onco Therapies has received final ANDA approval for Oxaliplatin Injection 50mg/10mL and 100mg/20mL. The company had in November 2011 received tentative approval from USFDA in November 2011 based on a Para III filing. This approval was later converted to a Para IV filing based on which USFDA has now granted final approval.
Oxaliplatin is part of the oncology portfolio licensed to Pfizer for the US market and the product is available for immediate launch. Oxaliplatin is a chemotherapy drug used to treat advanced cancer of the colon and rectum. It is used in combination with other medications to slow or stop cancer cell growth.
According to IMS data, the US market for generic Oxaliplatin is approximately $1.5 billion.
Strides Arcolab is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures wide range of IP-lead niche pharmaceutical products with an emphasis on sterile injectables.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1531.05 |
Dr. Reddys Lab | 6428.05 |
Cipla | 1482.30 |
Zydus Lifesciences | 1093.45 |
Lupin | 1637.60 |
View more.. |